International Agencies (Bangladesh) Ltd. (IABL) andEli Lilly and Company,has announced the launching of Humulin™KwikPen™(Human Insulin),prefilled Pen Devices in Bangladesh.
“Blood Sugar control is difficult to monitor diabetic patients. In Bangladesh, this acts as a barrier to treatment success. It is the need of the hour to have treatment solutions that help improve dosage accuracy, patient compliance and quality insulin treatments that ensure equitable access,” said National Prof. A K Azad Khan, President, BADAS.
“Humulin™KwikPen™will be in the market and distributed in Bangladesh by International Agencies (Bangladesh) Ltd.,a leading life sciences organization that believes in innovation, marketing and distribution of quality medicine, patient benefit and compliance.
The launch of Humulin™Kwikpen™will open up new avenues in diabetes management and provide health care professionals with an additionaloption to manage diabetes,” saidSwapan Kumar Modak, MD& CEO,International Agencies (Bangladesh) Ltd.
“Managing diabeteschallenging for the people living with this condition and it is also a burden on the healthcare systems in Bangladesh and across the globe.” said Luca Visini, Managing Director, India Subcontinent, Lilly India.
“Lilly has been a global leader in diabetes care since 1923. Humulin™Kwikpen™is a significant and innovative addition to our diabetes portfolio in Bangladesh.It is another important step in our journey to help more and more people living with Diabetesby providing them with innovative treatment support” he added.
Humulin™Kwikpen™is a prescription drug that should be taken only on advice from registered physicians. For prescribing information, please speak to your designated registered physician or health care provide, said a press release. .
